{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:31:56Z","timestamp":1782181916373,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Both the risk of developing heart disease and the course of the disease are determined in particular by comorbidities. In this context, gout has recently been identified as an important factor in influencing the development of cardiovascular events such as heart failure or coronary artery disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective cohort study compared the incidence of angina pectoris (AP) (ICD-10: I20), myocardial infarction (MI) (ICD-10: I21, I22), chronic coronary heart disease (CHD) (ICD-10: I25), atrial fibrillation (AF), and heart failure (HF) as a function of gout in Germany in a large collective of 66,000 gout patients in comparison to 66,000 individuals without gout between using propensity score matching (1:1) from January 2005 to December 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Within 10\u00a0years after the index date, AP was diagnosed in 5.2% of gout and 2.9% of non-gout patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), MI in 3.1% of gout and 2.2% of non-gout patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), CHD in 16.5% of gout and 11.8% of non-gout patients, AF in 12.6% of gout and 8.4% of non-gout patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and HF in 14.7% of gout and 8.5% of non-gout patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). For all diagnoses except CHD, the association was stronger in male than in female patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The relationship shown between gout and cardiovascular disease indicates that gout could be one of a series of inflammatory conditions that increase the risk of cardiac disease. The association we have shown between gout and all major cardiac diseases suggests that there is a risk modifier, the treatment of which could help prevent these diseases. Further research is needed to determine whether treating gout can effectively reduce this risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00392-024-02537-9","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:02:16Z","timestamp":1725969736000},"page":"1185-1190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The association between gout and subsequent cardiovascular events: a retrospective cohort study with 132,000 using propensity score matching in primary care outpatients in Germany"],"prefix":"10.1007","volume":"114","author":[{"given":"Jamschid","family":"Sedighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gaensbacher-Kunzendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sossalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"2537_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/2047487320957793","volume":"27","author":"A Tedeschi","year":"2020","unstructured":"Tedeschi A, Agostoni P, Pezzuto B et al (2020) Role of comorbidities in heart failure prognosis Part 2: chronic kidney disease, elevated serum uric acid. Eur J Prev Cardiol 27:35\u201345. https:\/\/doi.org\/10.1177\/2047487320957793","journal-title":"Eur J Prev Cardiol"},{"key":"2537_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"2537_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G et al (2022) Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 328:440\u2013450. https:\/\/doi.org\/10.1001\/jama.2022.11390","journal-title":"JAMA"},{"key":"2537_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/jim-2019-001140","volume":"68","author":"WS Huang","year":"2020","unstructured":"Huang WS, Lin CL, Tsai CH, Chang KH (2020) Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients. J Investig Med 68:972\u2013979. https:\/\/doi.org\/10.1136\/jim-2019-001140","journal-title":"J Investig Med"},{"key":"2537_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2047487313514895","volume":"22","author":"LE Clarson","year":"2015","unstructured":"Clarson LE, Chandratre P, Hider SL et al (2015) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 22:335\u2013343. https:\/\/doi.org\/10.1177\/2047487313514895","journal-title":"Eur J Prev Cardiol"},{"key":"2537_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 56:459\u2013466. https:\/\/doi.org\/10.5414\/CP203320","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2537_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582680","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu W, Cheng JD (2020) Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. Front Pharmacol 11:582680. https:\/\/doi.org\/10.3389\/fphar.2020.582680","journal-title":"Front Pharmacol"},{"key":"2537_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40265-019-01081-5","volume":"79","author":"MK Gupta","year":"2019","unstructured":"Gupta MK, Singh JA (2019) Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. Drugs 79:531\u2013541. https:\/\/doi.org\/10.1007\/s40265-019-01081-5","journal-title":"Drugs"},{"key":"2537_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099102","volume":"9","author":"VC Kok","year":"2014","unstructured":"Kok VC, Horng JT, Chang WS, Hong YF, Chang TH (2014) Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS\u00a0One 9:e99102. https:\/\/doi.org\/10.1371\/journal.pone.0099102","journal-title":"PLoS\u00a0One"},{"key":"2537_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie IS, Hawkey CJ, Ford I et al (2022) Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(22)01657-9","journal-title":"Lancet"},{"issue":"6","key":"2537_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ejhf.2433","volume":"24","author":"K McDowell","year":"2022","unstructured":"McDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, de Boer RA, O\u2019Meara E, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Hammarstedt A, Langkilde AM, Sj\u00f6strand M, Lindholm D, Solomon SD, Sattar N, Sabatine MS, McMurray JJV (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail 24(6):1066\u20131076. https:\/\/doi.org\/10.1002\/ejhf.2433. (Epub 2022 Feb 6. PMID: 35064721; PMCID: PMC9540869)","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2537_CR12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/ejhf.2516","volume":"24","author":"S Carter","year":"2022","unstructured":"Carter S, Hendren NS, Grodin JL (2022) Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation? Eur J Heart Fail 24(6):1077\u20131079. https:\/\/doi.org\/10.1002\/ejhf.2516. (Epub 2022 May 9 PMID: 35485178)","journal-title":"Eur J Heart Fail"},{"key":"2537_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2147\/IJGM.S300196","volume":"14","author":"H Yang","year":"2021","unstructured":"Yang H, Gao J, Li S et al (2021) Gender differences in the association between serum uric acid and arteriosclerotic cardiovascular risk among Chinese type 2 diabetes mellitus patients. Int J Gen Med 14:687\u2013695. https:\/\/doi.org\/10.2147\/IJGM.S300196","journal-title":"Int J Gen Med"},{"issue":"3","key":"2537_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/hr.2010.246","volume":"34","author":"R Rossi","year":"2011","unstructured":"Rossi R, Nuzzo A, Origliani G, Modena MG (2011) Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women. Hypertens Res 34(3):295\u2013300. https:\/\/doi.org\/10.1038\/hr.2010.246","journal-title":"Hypertens Res"},{"issue":"5","key":"2537_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","volume":"120","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120(5):442\u2013447. https:\/\/doi.org\/10.1016\/j.amjmed.2006.06.040","journal-title":"Am J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02537-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T07:05:36Z","timestamp":1756883136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02537-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2537"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02537-9","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}